IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.930
NA - Nord America 4.360
AS - Asia 4.267
SA - Sud America 750
AF - Africa 57
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 2
Totale 21.381
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 7.958
US - Stati Uniti d'America 4.274
SG - Singapore 1.635
IE - Irlanda 1.246
CN - Cina 876
HK - Hong Kong 758
IT - Italia 744
BR - Brasile 630
DE - Germania 441
GB - Regno Unito 407
UA - Ucraina 356
KR - Corea 294
FR - Francia 265
VN - Vietnam 239
FI - Finlandia 140
IN - India 127
SE - Svezia 113
GR - Grecia 105
TR - Turchia 97
JP - Giappone 78
CA - Canada 51
AR - Argentina 46
AT - Austria 35
PK - Pakistan 35
BD - Bangladesh 27
EC - Ecuador 24
NL - Olanda 23
ID - Indonesia 22
MX - Messico 22
BE - Belgio 21
IQ - Iraq 20
CZ - Repubblica Ceca 16
ZA - Sudafrica 15
PL - Polonia 13
ES - Italia 12
MA - Marocco 12
PY - Paraguay 9
VE - Venezuela 9
AU - Australia 8
BO - Bolivia 8
KE - Kenya 8
PE - Perù 8
CL - Cile 7
IR - Iran 7
NZ - Nuova Zelanda 7
AZ - Azerbaigian 6
CH - Svizzera 6
KG - Kirghizistan 6
CO - Colombia 5
SA - Arabia Saudita 5
TN - Tunisia 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
HU - Ungheria 4
IL - Israele 4
LT - Lituania 4
SN - Senegal 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
JO - Giordania 3
MK - Macedonia 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
BY - Bielorussia 2
ET - Etiopia 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
HN - Honduras 2
JM - Giamaica 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
NP - Nepal 2
RS - Serbia 2
TW - Taiwan 2
AM - Armenia 1
BG - Bulgaria 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
Totale 21.379
Salva come PNG Salva come JPEG
Città #
Moscow 2.853
Dublin 1.233
Hong Kong 755
Santa Clara 675
Singapore 672
Chandler 607
Jacksonville 581
Seoul 271
Princeton 170
Beijing 147
Bremen 145
Roxbury 142
New York 141
Medford 131
Hefei 128
Dallas 123
Ashburn 120
Naples 116
Ann Arbor 106
Munich 105
The Dalles 84
Ho Chi Minh City 81
Bengaluru 78
Wilmington 78
Caserta 76
São Paulo 67
Los Angeles 56
Boardman 54
Cambridge 45
Hanoi 44
Des Moines 42
San Mateo 41
Nanjing 38
Woodbridge 36
Napoli 32
Turku 32
Nuremberg 26
Elora 22
Falkenstein 22
Brussels 21
Tianjin 21
Brasília 20
Dong Ket 20
Norwalk 20
Vienna 20
Helsinki 17
Houston 17
Mountain View 17
Rio de Janeiro 17
Shanghai 17
Tokyo 16
Milan 15
Belo Horizonte 13
Brno 13
Brooklyn 13
Guangzhou 13
Nanchang 13
Columbus 12
Curitiba 12
Aversa 11
Istanbul 11
Jakarta 11
Düsseldorf 10
Haiphong 10
Lappeenranta 10
Quito 10
Redwood City 10
Rome 10
San Francisco 10
Amsterdam 9
Auburn Hills 9
Changsha 9
Hải Dương 9
Jinan 9
Warsaw 9
Bahawalpur 8
Council Bluffs 8
Da Nang 8
Ercolano 8
Frankfurt am Main 8
Guarulhos 8
London 8
Rawalpindi 8
Zhengzhou 8
Cava Dei Tirreni 7
Groningen 7
Hangzhou 7
Nairobi 7
Ninh Bình 7
Ottawa 7
Pozzuoli 7
Toronto 7
Venice 7
Baku 6
Bishkek 6
Campo Grande 6
Dhaka 6
Florence 6
Goiânia 6
Guayaquil 6
Totale 10.836
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 221
ONCOLOGIA MEDICA 197
Beyond N staging in colorectal cancer: Current approaches and future perspectives 196
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 192
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 191
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 173
AXL is an oncotarget in human colorectal cancer 172
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 168
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 165
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 165
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 164
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 164
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 161
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 158
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 157
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 156
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 154
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 150
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 149
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 147
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 146
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 146
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 145
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 145
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 144
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 144
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 144
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 143
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 138
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 138
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 138
The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria 137
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 136
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 134
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 134
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 134
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 134
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 132
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 131
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 130
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 130
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 128
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 128
Farmacogenomica e cancro colorettale 127
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 126
TRASTUZUMAB RESISTANCE IN BREAST CANCER 125
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 125
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 124
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 124
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 123
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 123
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 123
Light alcohol drinking and the risk of cancer development: a controversial relationship 123
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 122
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 122
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 121
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 121
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 121
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 121
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 119
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)] 118
Chemoradiotherapy as adjuvant treatment of gastric cancer 117
Targeting EGFR in Pancreatic Cancer Treatment. 117
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 117
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 117
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 116
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 115
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 115
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 114
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 114
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 114
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 113
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 113
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 112
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 112
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 111
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 111
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 110
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 110
Preoperative chemo-radiotherapy for carcinoma of the esophagus 110
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 110
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 110
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 110
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis 109
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 109
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 108
Pimasertib hydrochloride 108
Endoscopic calcium electroporation for unfit-for-surgery bleeding colorectal cancer: the dawn of a new treatment? 107
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 106
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 106
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ 106
Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report 105
Metformin in lung cancer: rationale for a combination therapy 105
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 105
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 105
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 105
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 105
It is finally time for adjuvant therapy in melanoma 105
The new European gold standard treatment for rectum cancer 104
Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report 104
Totale 13.057
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021557 0 0 0 0 0 12 129 95 34 116 120 51
2021/20221.151 54 17 23 23 340 20 42 35 54 99 106 338
2022/20232.473 251 50 34 212 291 208 7 151 1.149 17 57 46
2023/2024992 93 37 38 51 335 140 19 24 11 14 74 156
2024/20253.318 56 105 54 107 471 432 339 320 471 448 268 247
2025/202611.140 559 606 669 682 1.097 7.527 0 0 0 0 0 0
Totale 21.864